Mylan has launched its generic version ... The main patent on Advair (fluticasone+salmeterol) expired as long ago as 2010, while the patent on GSK’s Diskus inhaler expired in 2016.

Interventions: Patients entered a 4-week, open run-in period, receiving fluticasone propionate 50µg twice daily via a Diskus™ inhalation device. Patients whose asthma was well controlled ...

The U.S. Federal Trade Commission, which has warned pharmaceutical companies against submitting irrelevant patents to the FDA to limit generic competition, supported Amneal's lawsuit. A Teva ...

The US Court of Appeals for the Federal Circuit on Friday affirmed a lower district court order against Israeli pharmaceutical maker Teva Pharmaceutical Industries (NYSE: TEVA) requiring its US ...

The Annals of Pharmacotherapy. 2009;43(3):519-527.

Novartis has moved a step closer to EU approval of its three-drug asthma therapy Enerzair ... glycopyrronium, and inhaled corticosteroid (ICS) mometasone furoate, and is a close rival to GSK ...

of N.Y. LLC’s action alleging that Teva Branded Pharm. Prods. R&D Inc. improperly listed inhaler patents in the Orange Book and delayed the entry of generic products onto the market. The appeals court ...

In addition, insurance companies have not required prior treatment with generic fluticasone as a basis ... the US rights to Omnaris and Alvesco (an inhaled formulation of ciclesonide for asthma ...